Advertisement

Drugs

, Volume 52, Issue 5, pp 649–661 | Cite as

Choosing the Right Lipid-Regulating Agent

A Guide to Selection
  • John A. Farmer
  • Antonio M. GottoJr
Review Article

Summary

If dietary therapy and other lifestyle changes do not adequately normalise blood lipid levels, lipid-regulating drugs, as single-drug or combination-drug therapy, may be prescribed to supplement lifestyle changes. Evaluation of the individual patient’s health and risk status, determination of the dyslipidaemia, definition of treatment goals and a clear understanding of the mechanisms and effects of lipid-regulating agents are necessary for optimisation of treatment. Although all the available lipid-regulating agents lower low density lipoprotein (LDL) cholesterol, the agents with the greatest LDL cholesterol-lowering effect are the bile acid sequestrants, which up-regulate the LDL receptor by the decrease in intrahepatic cholesterol caused by the interruption of enterohepatic circulation of cholesterol-rich bile acids, and the HMG-CoA reductase inhibitors, which partially inhibit HMG-CoA reductase. The agents with the greatest triglyceride-lowering effect are nicotinic acid, which decreases the production of very low density lipoprotein (VLDL) cholesterol and reduces the availability of free fatty acids in the circulation, and the fibric acid derivatives, which increase lipoprotein lipase activity and may also decrease the release of free fatty acids. Although the safety profile of the available lipid-regulating drugs has been established, patients should be monitored for potential adverse effects and interactions with concomitantly administered agents. When used correctly, lipid-regulating drug therapy is highly effective in the treatment of a variety of dyslipidaemias.

Keywords

Nicotinic Acid Pravastatin Gemfibrozil High Density Lipoprotein Cholesterol Level Bile Acid Sequestrant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89: 1329–445Google Scholar
  2. 2.
    Farmer JA, Gotto Jr AM. Currently available hypolipidaemic drugs and future therapeutic developments. Baillieres Clin Endocrinol Metab 1995; 9: 825–47PubMedCrossRefGoogle Scholar
  3. 3.
    Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319: 24–33PubMedCrossRefGoogle Scholar
  4. 4.
    Kostner GM, Gavish D, Leopold B, et al. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989; 80: 1313–9PubMedCrossRefGoogle Scholar
  5. 5.
    Tsuda Y, Satoh K, Takahashi T, et al. Effect of medication with pravastatin sodium on hemorheological parameters in patients with hyperlipoproteinemia. Int Angiol 1993; 12: 360–4PubMedGoogle Scholar
  6. 6.
    Ernst E. Plasma fibrinogen—an independent cardiovascular risk factor. J Intern Med 1990; 227: 365–72PubMedCrossRefGoogle Scholar
  7. 7.
    Isaacsohn JL, Setaro JF, Nicholas C, et al. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels. Am J Cardiol 1994; 74: 735–7PubMedCrossRefGoogle Scholar
  8. 8.
    Wada H, Mori Y, Kaneko T, et al. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol 1993; 44: 112–6PubMedCrossRefGoogle Scholar
  9. 9.
    Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993; 70: 138–43PubMedGoogle Scholar
  10. 10.
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9Google Scholar
  11. 11.
    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–7PubMedCrossRefGoogle Scholar
  12. 12.
    Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation 1995; 92: 2419–25PubMedCrossRefGoogle Scholar
  13. 13.
    Kirby TJ. Cataracts produced by triparanol. Trans Am Ophthalmol Soc 1967; 65: 493–543Google Scholar
  14. 14.
    Tobert JA, Shear CL, Chremos AN, et al. Clinical experience with lovastatin. Am J Cardiol 1990; 65: 23F–6FPubMedCrossRefGoogle Scholar
  15. 15.
    Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71–5PubMedCrossRefGoogle Scholar
  16. 16.
    Spach DH, Bauwens JE, Clark CD, et al. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991; 154: 213–6PubMedGoogle Scholar
  17. 17.
    Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplant recipients. JAMA 1988; 260: 239–41PubMedCrossRefGoogle Scholar
  18. 18.
    Ast M, Frishman WH. Bile acid sequestrants. J Clin Pharmacol 1990; 30: 99–106PubMedGoogle Scholar
  19. 19.
    Moore RB, Crane CA, Frantz Jr ID. Effect of cholestyramine on the fecal excretion of intravenously administered cholesterol-4-14C and its degradation products in a hypercholesterolemic patient. J Clin Invest 1968; 47: 1664–71PubMedCrossRefGoogle Scholar
  20. 20.
    Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351–64CrossRefGoogle Scholar
  21. 21.
    Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289–98PubMedCrossRefGoogle Scholar
  22. 22.
    Gallo DG, Bailey KR, Sheffner AL. The interaction between cholestyramine and drugs. Proc Soc Exp Biol Med 1965; 120: 60–5PubMedGoogle Scholar
  23. 23.
    Bazzano G, Bazzano GS. Digitalis intoxication: treatment with a new steroid-binding resin. JAMA 1972; 220: 828–30PubMedCrossRefGoogle Scholar
  24. 24.
    Northcutt RC, Stiel JN, Hollifield JW, et al. The influence of cholestyramine on thyroxine absorption. JAMA 1969; 208: 1857–61PubMedCrossRefGoogle Scholar
  25. 25.
    Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Med Toxicol 1987; 2: 10–32PubMedCrossRefGoogle Scholar
  26. 26.
    Hunninghake DB, King S, LaCroix K. The effect of cholestyramine and colestipol on the absorption of hydrochlorothiazide. Int J Clin Pharmacol Ther Toxicol 1982; 20: 151–4PubMedGoogle Scholar
  27. 27.
    Shepherd J, Packard CJ, Patsch JR, et al. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 1979; 63: 858–67PubMedCrossRefGoogle Scholar
  28. 28.
    Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989; 226: 271–6PubMedCrossRefGoogle Scholar
  29. 29.
    Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360–81CrossRefGoogle Scholar
  30. 30.
    Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986; 8: 1245–55PubMedCrossRefGoogle Scholar
  31. 31.
    Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405–18PubMedCrossRefGoogle Scholar
  32. 32.
    Mullin GE, Greenson JK, Mitchell MC. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann Intern Med 1989; 111: 253–5PubMedGoogle Scholar
  33. 33.
    Litin SC, Anderson CF. Nicotinic acid-associated myopathy: a report of three cases. Am J Med 1989; 86: 481–3PubMedCrossRefGoogle Scholar
  34. 34.
    Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis [letter]. Ann Intern Med 1988; 109: 597–8PubMedGoogle Scholar
  35. 35.
    Brown WV, Howard WJ, Field L. Nicotinic acid and its derivatives. In: Rifkind BM, editor. Drug treatment of hyperlipidemia. New York: Marcel Dekker, 1991: 189–213Google Scholar
  36. 36.
    Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992; 92: 77–81PubMedCrossRefGoogle Scholar
  37. 37.
    Nikkila EA, Huttunen JK, Ehnholm C. Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia. Metabolism 1977; 26: 179–86PubMedCrossRefGoogle Scholar
  38. 38.
    Levy RI, Morganroth J, Rifkind BM. Treatment of hyperlipidemia. N Engl J Med 1976; 290: 1295–301CrossRefGoogle Scholar
  39. 39.
    Davignon J. Fibrates: a review of important issues and recent findings. Can J Cardiol 1994; 10 Suppl.B: 61B–71BGoogle Scholar
  40. 40.
    Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260: 1917–21PubMedCrossRefGoogle Scholar
  41. 41.
    Tsai MY, Yuan J, Hunninghake DB. Effect of gemfibrozil on composition of lipoproteins and distribution of LDL subspecies. Atherosclerosis 1992; 95: 35–42PubMedCrossRefGoogle Scholar
  42. 42.
    Eisenberg S, Gavish D, Oschry Y, et al. Abnormalities in very low, low, and high density lipoproteins in hypertriglyceridemia: reversal toward normal with bezafibrate treatment. J Clin Invest 1984; 74: 470–82PubMedCrossRefGoogle Scholar
  43. 43.
    Bo M, Bonino F, Neirotti M, et al. Hemorrheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs. Angiology 1991; 42: 106–13PubMedCrossRefGoogle Scholar
  44. 44.
    Andersen P, Smith P, Seljeflot I, et al. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. Thromb Haemost 1990; 63: 174–7PubMedGoogle Scholar
  45. 45.
    Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237–45PubMedCrossRefGoogle Scholar
  46. 46.
    Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992; 85: 37–45PubMedCrossRefGoogle Scholar
  47. 47.
    Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40: 1069–118CrossRefGoogle Scholar
  48. 48.
    Illingworth DR. Fibric acid derivatives. In: Rifkind BM, editor. Drug treatment of hyperlipidemia. New York: Marcel Dekker, 1991: 103–38Google Scholar
  49. 49.
    Sirtori CR, Calabresi L, Werba JP, et al. Tolerability of fibric acids. Comparative data and biochemical bases. Pharmacol Res 1992; 26: 243–60PubMedCrossRefGoogle Scholar
  50. 50.
    Langer T, Levy RI. Acute muscular syndrome associated with administration of clofibrate. N Engl J Med 1968; 279: 856–8PubMedCrossRefGoogle Scholar
  51. 51.
    Baker SG, Joffe BI, Mendelsohn D, et al. Treatment of homozygous familial hypercholesterolemia with probucol. S Afr Med J 1982; 62: 7–11PubMedGoogle Scholar
  52. 52.
    Yamamoto A, Matsuzawa Y, Yokoyama S, et al. Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol 1986; 57: 29H–35HPubMedCrossRefGoogle Scholar
  53. 53.
    Schmidt EB, Illingworth DR, Bacon S, et al. Hypolipidemic effects of nicotinic acid in patients with familial defective apolipoprotein B-100. Metabolism 1993; 42: 137–9PubMedCrossRefGoogle Scholar
  54. 54.
    Grundy SM. Multifactorial etiology of hypercholesterolemia: implications for prevention of coronary heart disease. Arterioscler Thromb 1991; 11: 1619–35PubMedCrossRefGoogle Scholar
  55. 55.
    American Diabetes Association. Detection and management of lipid disorders in diabetes. Diabetes Care 1993; 16 Suppl. 2: 106–12Google Scholar
  56. 56.
    Juhan-Vague I, Roui C, Alessi M, et al. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients: relationship with plasma insulin. Thromb Haemost 1989; 61: 370–3PubMedGoogle Scholar
  57. 57.
    Prata MM, Nogueira AC, Pinto JR, et al. Long-term effect of lovastatin on lipoprotein profile in patients with primary nephrotic syndrome. Clin Nephrol 1994; 41: 277–83PubMedGoogle Scholar
  58. 58.
    Knight RJ, Vathsala A, Schoenberg L, et al. Treatment of hyperlipidemia in renal transplant patients with gemfibrozil and dietary modification. Transplantation 1992; 53: 224–5PubMedGoogle Scholar
  59. 59.
    Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • John A. Farmer
    • 1
  • Antonio M. GottoJr
    • 2
  1. 1.Department of Medicine, Baylor College of Medicine, and Section of CardiologyBen Taub General HospitalHoustonUSA
  2. 2.Department of Medicine, Baylor College of Medicine, and Internal Medicine ServiceThe Methodist HospitalHoustonUSA

Personalised recommendations